COMPUMEDICS LIMITED (CMP)
Latest AI Signal: SELL
Status: AGING
Days Old: 7
Confidence: 65.00%
Date: 14-05-2026
Price: $0.280
Last Price: $0.280
Post-Signal Low Price: $0.280
Latest COMPUMEDICS LIMITED(CMP) News
19 Mar 2026, 07:30 PM
Custom Market Insights
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Intracranial Pressure Monitoring Devices Market size & share revenue was valued at approximately USD 1.89 Billion in 2025 and is expected to reach
21 Aug 2025, 09:30 PM
Custom Market Insights
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Non-invasive Brain Trauma Monitoring Device Market size & share revenue was valued at approximately USD 14.7 Billion in 2024 and is expected to r
Chart available once enough post-signal price data is available.
Sell Confidence Medium
AI Confidence - 65.00 % model confidence
Business Overview
Compumedics Limited is a medical device company specializing in advanced diagnostic equipment for sleep disorders, neurology, and brain research. It holds a niche market position with proprietary technology in polysomnography and neurodiagnostic systems, primarily serving hospitals and research institutions globally.
Financial Analysis
| Cash Flow | Weak |
| Debt | Moderate |
| Profitability | Weak |
| Revenue Trend | Downtrend |
Technical Analysis
| Trend | Bearish |
| Momentum | Weak |
| RSI Signal | Oversold |
| Support Level | $ 0.25 |
| Resistance Level | $ 0.35 |
Valuation
Valuation - Fairly Valued
Current price reflects challenges in revenue growth and profitability, with limited upside given market conditions.
Catalysts
• Potential new product launches or technology upgrades could drive future growth.
• Strategic partnerships or acquisitions to expand market presence.
• Improvement in global healthcare spending on diagnostic equipment.
Recommendation
Action - Sell
Timeframe - Short Term
Given the downtrend in financial performance, weak cash flow, and bearish technical signals, the stock is likely to face continued pressure. Investors should consider reducing exposure until clear signs of operational turnaround emerge.
